Development of ciclopirox nail lacquer with enhanced permeation and retention

被引:0
作者
Raj Kumar Thapa
Ju Yeon Choi
Toe Gyung Go
Min Hyung Kang
Sang Duk Han
Joon-Ho Jun
Mi Won Son
Chul Soon Yong
Jong Oh Kim
机构
[1] Yeungnam University,College of Pharmacy
[2] Pharmaceutical Product Research Laboratories,Dong
来源
Archives of Pharmacal Research | 2016年 / 39卷
关键词
Onychomycosis; Nail lacquer; Ciclopirox; Potassium hydroxide; Urea;
D O I
暂无
中图分类号
学科分类号
摘要
Onychomycosis is a prevailing disease caused by fungal infection of nails that mostly affects athletes and the elderly. Ciclopirox is approved by the US Food and Drug Administration for the topical treatment of onychomycosis. However, the desired penetration of ciclopirox into the nail bed has not been achieved via topical application for efficient treatment. Therefore, the main aim of this study was to enhance ciclopirox permeation and retention in nail by the development of a new nail lacquer formulation. We screened the effects of different solvents, alkalizing agents, and permeation enhancers on the permeation of bovine hooves by ciclopirox and its retention in human nail clippings. The results suggest that isopropyl alcohol, potassium hydroxide, and urea as the solvent, alkalizing agent, and permeation enhancer, respectively, improved the permeation of the ciclopirox nail lacquer formulation the most with high flux rates. Comparison of the final formulation and marketed product revealed enhanced retention of ciclopirox from our developed formulation in human nail clippings. Therefore, our newly developed nail lacquer may be a potentially effective formulation for the treatment of onychomycosis in humans.
引用
收藏
页码:953 / 959
页数:6
相关论文
共 120 条
[1]  
Baden HP(1973)A comparative study of the physicochemical properties of human keratinized tissues Biochim Biophys Acta 322 269-278
[2]  
Goldsmith LA(2005)Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy J Eur Acad Dermatol Venereol 19 21-29
[3]  
Fleming B(2009)An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis J Eur Acad Dermatol Venereol 23 773-781
[4]  
Baran R(2009)Overcoming the nail barrier: a systematic investigation of ungual chemical penetration enhancement Int J Pharm 370 61-67
[5]  
Kaoukhov A(2001)Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature J Eur Acad Dermatol Venereol 15 312-316
[6]  
Baran R(1996)Clinical and economic factors in the treatment of onychomycosis Pharmacoeconomics 9 307-320
[7]  
Tosti A(2010)Transungual drug delivery: current status Int J Pharm 384 1-8
[8]  
Hartmane I(2015)Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective J Control Release 199 132-144
[9]  
Altmeyer P(2003)Epidemiology, clinical presentation and diagnosis of onychomycosis Br J Dermatol 149 1-4
[10]  
Hercogova J(2008)The effect of humidity on the fracture properties of human fingernails J Exp Biol 211 3677-3681